What is the “revolving door” I’m always talking about? It’s this. The former head of the FDA now is in private industry and he’s proposing drastic cuts to the clinical trial process. Yet no one complains.
The council’s report establishes an ambitious, yet reachable, national goal: doubling the current annual output of new medicines for patients. We believe existing evidence suggests this goal can be met by altering the FDA’s onerous clinical-trial requirements.
Imagine if he went to work for a trial lawyer lobbying group and proposed allowing generics to update the warning label so consumers could sue them….